Stop TB Partnership

TB prevalence survey in Bangladesh commences


25 March 2015 - National TB Prevalence survey has started from March 2015. Pre-survey field test started from December 2014, in institutional and community settings. Pilot surveys in both urban and rural cluster were conducted in January and February 2015. Due to few challenges, it was uncertain to start the survey. But the research team worked out coping strategy for working in challenging condition, and was successful to initiate the survey. At first, urban clusters in Dhaka City is being surveyed. Till date survey has been completed in six clusters, and rest six cluster will be covered within April 2015 in this phase.

Bangladesh is one of the twenty-two high burden countries for TB in the world. Reduction in TB prevalence is one of the Millennium Development Goals (MDGs) and an indicator within the Global Stop TB Plan. The Government of Bangladesh is conducting the TB prevalence survey for baseline information, WHO is supporting technically. The objectives of the survey are: to determine the prevalence of (a) bacteriologically confirmed pulmonary Tuberculosis cases (culture + GeneXpert) among =15 years; (b) smear positive pulmonary TB among the population aged =15 years; (c) symptoms suggestive of TB.

The sample size was estimated by stratified cluster sampling. The sample size is 100,000; number of clusters 125; clusters have been stratified in urban (46) and rural (79) and selected according to probability proportional to size (PPS). The participants in each cluster is 800±80.

Census is followed by survey. Informed written consent is taken from each participants or from legal guardian of participants <18 years. Local travel allowance is provided to each participant for each visit. Participants are interviewed for TB symptoms and chest X-Ray done for screening. Who are screened positive either by interview or/and X-ray are requested to provide a spot sputum sample followed by next morning sputum. The sputum is examined at the National Tuberculosis Reference Laboratory (NTRL) for smear, culture and GeneXpert. The chest X-ray, sputum examination findings and symptoms are reviewed by a central panel of experts. If any participant found positive for TB, s/he is contacted and is provided treatment by the NTP as per national guideline.

The survey is regularly monitored by TB Task Force at WHO HQ at Geneva, US CDC and RIT (JATA).

Submitted by: M Mushtuq Husain and Mahmudur Rahman

Institute of Epidemiology, Disease Control & Research (IEDCR), Dhaka 1212, BANGLADESH www.iedcr.gov.bd

For correspondence: mushtuq@dr.com